Bayer Pharma AG


Atrial Fibrillation (AF)

Atrial Fibrillation (AF)

Since 2001, several major medical registries and non-interventional studies have been launched to assess real-world outcomes in patients with atrial fibrillation (AF). These include: The Dresden NOAC registry; GARFIELD-AF – Global Anticoagulant Registry in the FIELD; RecordAF – REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation; ORBIT-AF – Outcomes Registry for Better Informed Treatment of Atrial Fibrillation; Paul Coverdell National Acute Stroke Registry; GLORIATM-AF – GLObal RegIstry on long-term oral Anti-thrombotic treatment in patients with Atrial Fibrillation; RealiseAF – ReaL-life global survey evaluating patients with Atrial Fibrillation; PREFER in AF – PREvention oF thromboembolic events – European Registry in Atrial Fibrillation; AFNET – The Central Registry of the German Competence NETwork on Atrial Fibrillation; and XANTUS – Xarelto® on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation.


Venous Thromboembolism (VTE)

Several major medical registries and non-interventional studies have been initiated to assess real-world outcomes in patients at risk of, or with, venous thromboembolism (VTE). These include: XAMOS – XArelto® in the prophylaxis of post-surgical venous thromboembolism after elective Major Orthopaedic Surgery of hip or knee; GLORY – Global Orthopaedic Registry; IMPROVE – International Medical Prevention Registry on Venous Thromboembolism; ENDORSE – Epidemiologic International Day for the Evaluation of Patients at Risk for Venous Thromboembolism in the Acute Hospital Care Setting; RIETE – Computerized registry of patients with venous thromboembolism – Registro Informatizado de Pacientes con Enfermedad TromboEmbólica; GARFIELD-VTE – Global Anticoagulant Registry in the FIELD; XALIA – XArelto® for Long-term and Initial Anticoagulation in venous thromboembolism; and PREFER in VTE – Prevention of Thromboembolic Events – European Registry in Venous Thromboembolism.


ACS Registries

Several major medical registries and non-interventional studies have been launched to assess real-world outcomes in patients with acute coronary syndrome (ACS). These registries include: GRACE – Global Registry of Acute Coronary Events; Euro Heart Survey on ACS; and ACTION Registry–Get with the Guidelines (GWTG).


Expanding Real-Life Knowledge

Registries that record real-world patient outcomes serve many important functions, identifying unmet patient needs and verifying the safety and efficacy of newly introduced therapies. This verification role is important as outcomes in clinical trials may not always reflect what is achieved in practice. Over the past two decades, several major medical registries and non-interventional studies have been launched across many therapy areas in which anticoagulant therapy is used, including: secondary prevention of acute coronary syndrome (ACS); stroke prevention in patients with atrial fibrillation (AF); and prevention and treatment of venous thromboembolism (VTE).